MORPHOSYS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67 EUR | 0.00% |
|
+0.53% | +97.06% |
| 05-06 | MORPHOSYS : UBS reiterates its Neutral rating | ZD |
| 04-30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
Presenter SpeechJames Quigley (Analysts)Great. So let's kick off. So, good afternoon, everyone...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
67
EUR
Average target price
58.71
EUR
Spread / Average Target
-12.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +97.06% | 2.72B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- MOR Stock
- News MorphoSys AG
- Transcript : MorphoSys AG Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 02